Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $902.64 | 10 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $268.33 | 3 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $201.50 | 2 | $0 (2017) |
| Genentech USA, Inc. | $192.27 | 2 | $0 (2018) |
| Bayer Healthcare Pharmaceuticals Inc. | $87.94 | 1 | $0 (2024) |
| Janssen Biotech, Inc. | $85.35 | 1 | $0 (2024) |
| Eisai Inc. | $67.25 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $173.29 | 2 | Bayer Healthcare Pharmaceuticals Inc. ($87.94) |
| 2023 | $67.25 | 1 | Eisai Inc. ($67.25) |
| 2019 | $100.52 | 1 | E.R. Squibb & Sons, L.L.C. ($100.52) |
| 2018 | $99.38 | 1 | Genentech USA, Inc. ($99.38) |
| 2017 | $462.20 | 5 | AstraZeneca Pharmaceuticals LP ($201.50) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $87.94 | General |
| Category: Oncology | ||||||
| 01/23/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $85.35 | General |
| Category: Oncology | ||||||
| 01/26/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $67.25 | General |
| Category: Oncology | ||||||
| 12/12/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $100.52 | General |
| Category: Oncology | ||||||
| 04/12/2018 | Genentech USA, Inc. | Avastin (Biological) | Food and Beverage | In-kind items and services | $99.38 | General |
| Category: BioOncology | ||||||
| 11/09/2017 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $114.25 | General |
| Category: Oncology | ||||||
| 08/24/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $88.20 | General |
| Category: Oncology | ||||||
| 06/22/2017 | Genentech USA, Inc. | Esbriet (Biological) | Food and Beverage | In-kind items and services | $92.89 | General |
| Category: Immunology | ||||||
| 02/23/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $79.61 | General |
| Category: Oncology | ||||||
| 01/19/2017 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $87.25 | General |
| Category: Oncology | ||||||
About Dr. Henry Maxwell, MD
Dr. Henry Maxwell, MD is a Surgery healthcare provider based in Gettysburg, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2013. The National Provider Identifier (NPI) number assigned to this provider is 1164869111.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Henry Maxwell, MD has received a total of $902.64 in payments from pharmaceutical and medical device companies, with $173.29 received in 2024. These payments were reported across 10 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($902.64).
Practice Information
- Specialty Surgery
- Location Gettysburg, PA
- Active Since 05/31/2013
- Last Updated 05/31/2013
- Taxonomy Code 208600000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1164869111
Products in Payments
- OPDIVO (Biological) $268.33
- IMFINZI (Drug) $114.25
- Avastin (Biological) $99.38
- Esbriet (Biological) $92.89
- Nubeqa (Drug) $87.94
- TAGRISSO (Drug) $87.25
- ERLEADA (Drug) $85.35
- Lenvima (Drug) $67.25
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.